ID   HCC827CLR
AC   CVCL_V406
DR   cancercelllines; CVCL_V406
DR   Cosmic; 1604992
DR   Wikidata; Q54881808
RX   PubMed=22133747;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_90180; CL-387785 (EKI-785).
CC   Selected for resistance to: ChEBI; CHEBI_114785; Erlotinib.
CC   Selected for resistance to: ChEBI; CHEBI_90197; PHA-665752.
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_V407 ! HCC827EPR
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 15
//
RX   PubMed=22133747; DOI=10.1016/j.lungcan.2011.11.007;
RA   Suda K., Tomizawa K., Osada H., Maehara Y., Yatabe Y., Sekido Y.,
RA   Mitsudomi T.;
RT   "Conversion from the 'oncogene addiction' to 'drug addiction' by
RT   intensive inhibition of the EGFR and MET in lung cancer with
RT   activating EGFR mutation.";
RL   Lung Cancer 76:292-299(2012).
//